BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Echosens' FibroScan(R) Expands its Application to NASH/NAFLD Patients


2/4/2010 12:40:42 PM

PARIS, FRANCE--(Marketwire - February 04, 2010) - NAFLD is the most common cause of liver disease worldwide. Determining a prognosis for this condition is today difficult as there are no clear predictors of which case NAFLD becomes NASH and then lead to some risks for patients.

Liver biopsy is the existing standard for diagnosis but difficult to perform just on suspicion.

To meet the urgent need for non invasive alternative two teams of experts from France (head by Pr de Ledinghen) and Hong Kong (head by Pr Wong(1)) demonstrate that the FibroScan® can be the revolutionary tool that the clinical practitioners dream of.

Pr Wong's publication concludes that liver stiffness is not affected by hepatic steatosis, necroinflammation or body mass index. It shows that FibroScan® seems to have a good accuracy to distinguish NASH patients into NAFLD population. Liver biopsy length is the only independent factor associated with discordance between FibroScan® and histology. Finally, FibroScan® performs significantly better than all studied blood markers (AST/ALT, APRI, FIB-4, NAFLD fibrosis score, BARD score) for both F3 and F4 on NAFLD patients.

In conclusion, the main value of the FibroScan® would be to exclude advanced fibrosis in NAFLD patients and provide clinicians with a better follow-up for at risk population or a better indication for biopsy.

Echosens: Partner for diagnostic solutions in Hepatology

A French company founded in 2001 in Paris, Echosens is an international SME specializing in the field of hepatology. The company developed and manufactures the FibroScan® device, based on VCTE™ "Vibration Controlled Transcient Elastography". Echosens has changed hepatologists' clinical practices by making available to them a new tool for diagnosis and follow-up of liver diseases. Echosens dedicates a significant part of its activity to Research in order to develop new medical devices and to open up new medical perspectives. The company works in close cooperation with health professionals and patients' associations to facilitate therapeutic follow up of patients. To date, 645 FibroScan® devices have been installed worldwide, including 157 in France. HAS (Health French Authority) validated the Fibroscan® for the diagnosis of HCV and HIV-HCV

For more information: www.echosens.com

Press kit available on demand.

(1) Wong et al. (2010). Hepatology 51(2), Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in non-alcoholic fatty liver disease


Contacts:
Echosens
Cecile Guiducci
International Marketing Director
+33 1 44 82 78 50
communication@echosens.com



Read at BioSpace.com

Echosens
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES